SensoDetect

SensoDetect AB recently completed a presentation at the Redeye Theme: Medtech & Diagnostics event, where CEO PA Hedin and Dr. Mohamed Hussein Atwa discussed the company's advancements and strategies in neuro-auditory screening. The presentation highlighted the challenges in traditional mental health assessments, such as ADHD and autism, which are often slow and subjective. SensoDetect offers a faster, objective solution through its BERA-based screening, which involves a brief auditory test and quick AI-driven analysis to assess risk levels. The company is transitioning from a niche diagnostic tool to a broader screening platform, targeting environments like schools and corporations. They have identified a significant market opportunity in the ADHD and autism sectors, which are valued at over USD 500 billion globally. SensoDetect's business model includes device sales, placements, and per-screening revenue, with AI improvements strengthening their competitive position. The presentation also covered strategic growth areas, including ADHD clinical support centers, school-based screening, and early childhood programs. SensoDetect's technology measures neural timing and brainstem connectivity, offering early detection of neurodevelopmental issues. SensoDetect is expanding into China and the MENA region, aligning with local policies and conducting large-scale pilots. The company aims to standardize its screening globally by 2028, with plans for a Neuro Status Index and integration into neonatal programs. CEO PA Hedin emphasized the company's mission to provide clarity for families and redefine mental health screening, while Dr. Atwa highlighted the shift from subjective observation to measurable brain data. For more information, interested parties can contact PA Hedin directly.

SensoDetect AB meddelar att VD PA Hedin och Dr. Mohamed Hussein Atwa, Global Head of Clinical Research, kommer att presentera vid Redeye Theme: Medtech & Diagnostics den 12 november 2025. Presentationen, som hålls på engelska, kommer att vara 12 minuter lång följt av en 8 minuters frågestund. Eventet är det tolfte årliga Redeye-eventet med fokus på Medtech & Diagnostics-sektorn och kommer att inledas med en marknadsintroduktion av Redeyes analytiker. Presentationer från utvalda företag kommer att följa, och investerare kommer att delta både på plats och via livestream. Tittare kan ställa frågor direkt via eventets sida, med frågestunden modererad av Redeyes analytikerteam. PA Hedin och Dr. Mohamed Hussein Atwa framhåller SensoDetects framsteg inom neuro-auditiv hjärnskanning och dess kliniska arbete som visar stark konsistens och tillämplighet. En inspelning av presentationen kommer att finnas tillgänglig på Redeyes plattform efter eventet. För mer information eller partnerskapsförfrågningar kan PA Hedin kontaktas.

SensoDetect AB will visit China from November 16–30, 2025, to advance their joint venture with Beijing Mind Exploration Medical Technology Co., Ltd. The delegation, including key company figures, aims to meet with clinical, regulatory, and industrial partners in Beijing and Shenzhen. The focus is on finalizing clinical pathways, advancing regulatory processes, and scaling up sales and marketing efforts. The trip's agenda includes clinical collaboration meetings, regulatory planning, and manufacturing reviews. The Q3 report release has been delayed to November 27 due to this trip.

A delegation from SensoDetect, including key figures such as Dr. Mohamed Hussein Atwa Ahmed, Ahmad Alosta, and Maher Almajzoub, discussed their updated market strategy, which involves two commercial models: Private School Screening Programs and SensoDetect-Owned Screening Centers. These initiatives aim to provide neuro-auditory screening for early identification of neurodevelopmental conditions. CEO PA Hedin highlighted growing regional interest in structured screening, which combines school programs with company-owned centers for better accessibility and long-term presence. An ongoing autism study led by Dr. Fatimah is progressing as planned, with upcoming data expected to enhance screening and referral processes. The SensoDetect BERA method is seen as aligning well with current educational and healthcare initiatives. The company is engaging with school networks to integrate structured screening into student health programs, and emphasizes local coordination for sustainable implementation. Further updates will follow as agreements are finalized.

The delegation from SensoDetect, including key figures like Dr. Mohamed Hussein Atwa Ahmed and Ahmad Alosta, has introduced an updated market strategy featuring two commercial models: Private School Screening Programs and SensoDetect-Owned Screening Centers. These models aim to provide standardized neuro-auditory screening to identify neurodevelopmental conditions early. CEO PA Hedin emphasized the growing interest in structured screening in the region and the importance of combining school programs with company-owned centers for accessibility and long-term presence. An ongoing autism study is on track, with future data expected to enhance screening workflows. Dr. Mohamed emphasized the alignment of the SensoDetect BERA method with current initiatives, while Mrs. Neven Ahmad highlighted the test's impact on families. Ahmad Alosta noted the openness of school networks to integrate screening into student health programs, and Maher Almajzoub stressed the importance of local coordination for sustained adoption. Further updates will follow as agreements are finalized.

SensoDetect AB has announced that it has received all license payments from its joint venture with Beijing Mind Exploration Medical Technology Co., Ltd. on time. The company reports significant progress in their collaboration, with the successful installation and activation of their AI software in Beijing. Early tests show that their BERA 4.2 system can now complete neurophysiological tests in under 5 minutes and 30 seconds, with AI calculations taking less than 10 seconds. This advancement improves the system's speed, efficiency, and reliability for clinical and research applications. CEO Per-Anders Hedin expressed satisfaction with the financial and technological developments, highlighting the potential of their technology to enhance clinical diagnostics. The company plans to proceed with further clinical validation, regulatory preparations, and production scaling. This follows a recent investment round aimed at supporting a large-scale launch in China. For further information, contact CEO PA Hedin.

SensoDetect AB has completed its initial investment round in its Chinese joint venture, Beijing Mind Exploration Medical Technology Co., Ltd. Two key investors, Mr. Lu Zhong and Mr. Lu Weihua, have joined the venture. Mr. Lu Zhong is a prominent figure in China's technology and investment sectors with significant experience, while Mr. Lu Weihua is a legal and investment expert with connections to a large investment consortium. Their involvement strengthens the joint venture's capital and positions it for the commercialization of SensoDetect's technologies in China. The company will now focus on clinical validation and market readiness.

SensoDetect Aktiebolag har meddelats att en aktieägares innehav har passerat vissa gränsvärden för aktier och röster, vilket företaget enligt Spotlight Stock Markets regler måste offentliggöra. Företagets största aktieägare, Thomas Holmgren, har avlidit och innan sin död överlät han 4,98 procent av sitt aktieinnehav i företaget till sina anhöriga. Före överlåtelsen ägde Holmgren 15,18 procent av kapitalet och rösterna i företaget. Efter överlåtelsen uppgår innehavet till 45,114,213 aktier, motsvarande 10,20 procent av kapitalet och rösterna i företaget. En uppdaterad lista över företagets tio största aktieägare kommer att publiceras på företagets webbplats. VD Per-Anders Hedin uttrycker sin tacksamhet för Holmgren, som var en betydande aktieägare och stödjare av företaget, och betonar hans inflytande och arv. Informationen offentliggjordes enligt lag den 14 oktober 2025. För ytterligare information kan VD PA Hedin kontaktas.

SensoDetect AB has announced new international collaborations to advance its clinical validation program for neuropsychiatric diagnostics. The company plans to launch initiatives with partners in the Middle East, Europe, and Asia to enhance its clinical reach and support its sales and marketing strategies. A significant part of this effort is an ongoing autism spectrum disorder study in Saudi Arabia, which is being bolstered with additional resources and partnerships. SensoDetect is also preparing data collection programs for ADHD research using advanced technology. Dr. Fatimah Saeed Alahmari has been appointed as a medical advisor to optimize the Saudi study and facilitate data collection. Her appointment underscores the company's commitment to the Middle East. CEO P-A Hedin emphasized the importance of these collaborations and announced future partnerships. Dr. Mohamed Atwa has moved to Sweden to work closely with the R&D team, and CEO Hedin will visit Dubai to strengthen regional relationships. These efforts aim to establish SensoDetect as a leader in neuropsychiatric diagnostic tools.

SensoDetect AB, a company specializing in tools for neurodevelopmental disorders, has appointed Dr. Fatimah Saeed Alahmari as its new Medical Advisor. Dr. Alahmari, a Developmental and Behavioural Paediatrician, brings over 20 years of experience and is currently involved in key healthcare roles in Saudi Arabia. Her appointment is part of SensoDetect's strategy to enhance its technology's clinical validation in the MENA region. Dr. Alahmari's connections and expertise will support large-scale data collection and integration of SensoDetect's solutions into clinical settings. She is committed to using technology to improve diagnostics for autism and ADHD. This move is expected to advance SensoDetect's clinical validation and regulatory approval processes.